Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | FGFR1 |
| Variant | C381R |
| Impact List | missense |
| Protein Effect | gain of function |
| Gene Variant Descriptions | FGFR1 C381R lies within the transmembrane domain of the Fgfr1 protein (UniProt.org). C381R is associated with increased phospho-Erk1/2 staining in a patient tumor sample (PMID: 30385747), increased proliferation and anchorage-independent colony formation in culture (PMID: 40526877), and the corresponding variant in an alternate isoform (C379R) demonstrates constitutive Fgfr1 activity in a luciferase assay and increased Erk1/2 phosphorylation in cell culture (PMID: 26272615). |
| Associated Drug Resistance | |
| Category Variants Paths |
FGFR1 mutant FGFR1 act mut FGFR1 C381R |
| Transcript | NM_023110.3 |
| gDNA | chr8:g.38419676A>G |
| cDNA | c.1141T>C |
| Protein | p.C381R |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| XM_006716304 | chr8:g.38419676A>G | c.1141T>C | p.C381R | RefSeq | GRCh38/hg38 |
| XM_006716303.3 | chr8:g.38419676A>G | c.1141T>C | p.C381R | RefSeq | GRCh38/hg38 |
| NM_001174064 | chr8:g.38419652A>G | c.1141T>C | p.C381R | RefSeq | GRCh38/hg38 |
| XM_017013221.1 | chr8:g.38419676A>G | c.1141T>C | p.C381R | RefSeq | GRCh38/hg38 |
| XM_024447097.1 | chr8:g.38419652A>G | c.1141T>C | p.C381R | RefSeq | GRCh38/hg38 |
| XM_017013221 | chr8:g.38419676A>G | c.1141T>C | p.C381R | RefSeq | GRCh38/hg38 |
| XM_006716309 | chr8:g.38419652A>G | c.1141T>C | p.C381R | RefSeq | GRCh38/hg38 |
| XM_006716303 | chr8:g.38419676A>G | c.1141T>C | p.C381R | RefSeq | GRCh38/hg38 |
| XM_017013221.2 | chr8:g.38419676A>G | c.1141T>C | p.C381R | RefSeq | GRCh38/hg38 |
| NM_023110.2 | chr8:g.38419676A>G | c.1141T>C | p.C381R | RefSeq | GRCh38/hg38 |
| XM_017013222.2 | chr8:g.38419676A>G | c.1141T>C | p.C381R | RefSeq | GRCh38/hg38 |
| XM_047421570.1 | chr8:g.38419676A>G | c.1141T>C | p.C381R | RefSeq | GRCh38/hg38 |
| XM_006716304.1 | chr8:g.38419676A>G | c.1141T>C | p.C381R | RefSeq | GRCh38/hg38 |
| NM_023110.3 | chr8:g.38419676A>G | c.1141T>C | p.C381R | RefSeq | GRCh38/hg38 |
| NM_023110 | chr8:g.38419676A>G | c.1141T>C | p.C381R | RefSeq | GRCh38/hg38 |
| XM_017013222 | chr8:g.38419676A>G | c.1141T>C | p.C381R | RefSeq | GRCh38/hg38 |
| NM_001174064.2 | chr8:g.38419652A>G | c.1141T>C | p.C381R | RefSeq | GRCh38/hg38 |
| XM_006716303.4 | chr8:g.38419676A>G | c.1141T>C | p.C381R | RefSeq | GRCh38/hg38 |
| NM_001174063 | chr8:g.38419676A>G | c.1141T>C | p.C381R | RefSeq | GRCh38/hg38 |
| XM_006716304.2 | chr8:g.38419676A>G | c.1141T>C | p.C381R | RefSeq | GRCh38/hg38 |
| XM_024447097.1 | chr8:g.38419652A>G | c.1141T>C | p.C381R | RefSeq | GRCh38/hg38 |
| NM_001174064.1 | chr8:g.38419652A>G | c.1141T>C | p.C381R | RefSeq | GRCh38/hg38 |
| NM_001174063.2 | chr8:g.38419676A>G | c.1141T>C | p.C381R | RefSeq | GRCh38/hg38 |
| NM_001174063.1 | chr8:g.38419676A>G | c.1141T>C | p.C381R | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR1 C381R | Advanced Solid Tumor | sensitive | Erdafitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Balversa (erdafitinib) inhibited colony formation and viability in cells expressing FGFR1 C381R in culture (PMID: 40526877). | 40526877 |
| FGFR1 C381R | Advanced Solid Tumor | sensitive | Futibatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Lytgobi (futibatinib) inhibited viability of cells expressing FGFR1 C381R in culture (PMID: 40526877). | 40526877 |
| FGFR1 C381R | Advanced Solid Tumor | sensitive | Pemigatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Pemazyre (pemigatinib) inhibited viability of cells expressing FGFR1 C381R in culture (PMID: 40526877). | 40526877 |
| FGFR1 C381R | Advanced Solid Tumor | sensitive | Fexagratinib | Preclinical - Cell culture | Actionable | In a preclinical study, Fexagratinib (AZD4547) inhibited viability of cells expressing FGFR1 C381R in culture (PMID: 40526877). | 40526877 |